Skip to content
BidBenchmark

Contractor

OSIVAX

PARIS 8
UEI
M4YDKJJRJYC7
Parent UEI
M4YDKJJRJYC7
Resolved by
uei
Confidence
1.000
Obligated to date
$20,229,3611
Awards
2
Agencies served
1

Active from Sep 19, 2025 to Sep 14, 2026.

Sign in to watch

Recent awards

AwardAgencyPlaceFirst actionCurrent value
75A50125C00006

OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.

Department of Health and Human Services—Sep 19, 2025$743,969
75A50125C00008

OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS

Department of Health and Human Services—May 19, 2026$19,485,392

Sources and method

Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.

Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.

  1. 1Awards are attributed by Unique Entity Identifier M4YDKJJRJYC7, the government's own recipient identifier, not by name matching.
  2. 2Award records from USAspending.gov, last refreshed Sep 24, 2026.
OSIVAX federal contracts · BidBenchmark